Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy.
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
We investigated the effect of the histone deacetylase inhibitors (HDIs), trichostatin A and trapoxin A on leukemia cells and cell lines from the viewpoint of differentiation induction. TSA induced differentiation in erythroid cell lines by itself, whereas it synergistically enhanced the differentiation that was directed by all-trans retinoic acid (ATRA) or vitamin D3 in U937, HL60 and NB4 cells. The combined treatment of HDI with ATRA induced differentiation in ATRA-resistant HL60 and NB4 cells. The transcriptional expression during the treatment with HDI was examined in HL60, U937 and MEG-O1. Cell cycle-regulator genes (p21waf1 and p16INK4A) were upregulated or constantly expressed, erythroid-specific genes (GATA-1, beta-globin) were silent or downregulated, and housekeeping genes (beta-actin and GAPDH) were constantly expressed. Twelve of 35 (34%) clinical samples from AML patients ranging from M0 to M7 also displayed both phenotypical and morphological changes by the treatment with TSA alone. HDIs are thus the potent inducer or enhancer of differentiation in acute myeloid leukemia and regulate transcription in an ordered manner.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inhibitors of HDAC are known to differentiate AML cells.40,45–47”
From RUNX1 regulates corepressor interactions of PU.1 (2011) · cites this paper as [46]
In the citing paper
“inhibition of HDAC1 and HDAC2, chromatin-modifying enzyme components of the SIN3A and NURD corepressor families aberrantly recruited to Pu.1 in Runx1-deficient cells, also restored expression of epigenetically repressed differentiation genes and terminal maturation (38–41”
From Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy (2014) · cites this paper as [39]
Citations
Cites
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases
Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., & Nakatani, Y. (1996) · Cell · doi:10.1016/s0092-8674(00)82001-2 · Cited by 2,952
Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription
Jones, P. L., Veenstra, G. J. C., Wade, P. A., Vermaak, D., Kass, S. U., Landsberger, N., Strouboulis, J., & Wolffe, A. P. (1998) · Nature Genetics · doi:10.1038/561 · Cited by 2,730
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Oncogenic Transcription Factors in the Human Acute Leukemias
Look, A. T. (1997) · Science · doi:10.1126/science.278.5340.1059 · Cited by 1,187
Role of the histone deacetylase complex in acute promyelocytic leukaemia
Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., & Evans, R. M. (1998) · Nature · doi:10.1038/35895 · Cited by 1,062
Grignani, F., De Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M., Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., et al. (1998) · Nature · doi:10.1038/35901 · Cited by 1,004
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Liu, M., Lee, M. H., Cohen, M., Bommakanti, M., & Freedman, L. P. (1996) · Genes & Development · doi:10.1101/gad.10.2.142 · Cited by 890
Yoshida, M., Horinouchi, S., & Beppu, T. (1995) · BioEssays · doi:10.1002/bies.950170510 · Cited by 713
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 694
Shivdasani, R. A., Fujiwara, Y., McDevitt, M. A., & Orkin, S. H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3965 · Cited by 674
(1996) · Europe PMC (PubMed Central) · Cited by 659
Rundlett, S. E., Carmen, A. A., Kobayashi, R., Bavykin, S., Turner, B. M., & Grunstein, M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14503 · Cited by 621
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B.
Herman, J. G., Jen, J., Merlo, A. U., & Baylin, S. B. (1996) · PubMed · Cited by 571
He, L.-Z., Guidez, F., Tribioli, C., Peruzzi, D., Ruthardt, M., Zelent, A., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/ng0298-126 · Cited by 557
Warrell, R. P., He, L.-Z., Richon, V., Calleja, E., & Pandolfi, P. P. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1621 · Cited by 502
Jiang, H., Lin, J., Su, Z., Collart, F., Huberman, E., & Fisher, P. B. (1994) · PubMed · Cited by 495
FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor
Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., & Horinouchi, S. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4027 · Cited by 487
Medina, V., Edmonds, B., Young, G. P., James, R., Appleton, S., & Zalewski, P. D. (1997) · PubMed · Cited by 377
Zhang, W., & Bieker, J. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9855 · Cited by 342
Histone Deacetylase Inhibitor Activates the WAF1/Cip1 Gene Promoter through the Sp1 Sites
Sowa, Y., Orita, T., Minamikawa, S., Nakano, K., Mizuno, T., Nomura, H., & Sakai, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7786 · Cited by 288
Wolffe, A. P. (1997) · Nature · doi:10.1038/387016a0 · Cited by 282
Yoshida, H., Kitamura, K., Tanaka, K., Ōmura, S., Miyazaki, T., Hachiya, T., Ohno, R., & Naoe, T. (1996) · PubMed · Cited by 249
Self-citationHistone Acetylation and Chromatin Assembly: A Single Escort, Multiple Dances?
Roth, S. Y., & Allis, C. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81316-1 · Cited by 248
ITAZAKI, H., NAGASHIMA, K., SUGITA, K., YOSHIDA, H., KAWAMURA, Y., YASUDA, Y., MATSUMOTO, K., ISHII, K., UOTANI, N., NAKAI, H., et al. (1990) · The Journal of Antibiotics · doi:10.7164/antibiotics.43.1524 · Cited by 197
Kwon, H. J., Owa, T., Hassig, C. A., Shimada, J., & Schreiber, S. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3356 · Cited by 197
Matsumura, I., Ishikawa, J., Nakajima, K., Oritani, K., Tomiyama, Y., Miyagawa, J.-I., Kato, T., Miyazaki, H., Matsuzawa, Y., & Kanakura, Y. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.5.2933 · Cited by 190
Hoshikawa, Y., Kwon, H. J., Yoshida, M., Horinouchi, S., & Beppu, T. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1248 · Cited by 188
Effects of trichostatins on differentiation of murine erythroleukemia cells.
Yoshida, M., Nomura, S., & Beppu, T. (1987) · PubMed · Cited by 169
Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias
Ogawa, S., Hirano, N., Sato, N., Takahashi, T., Hangaishi, A., Tanaka, K., Kurokawa, M., Tanaka, T., Mitani, K., & Yazaki, Y. (1994) · Blood · doi:10.1182/blood.v84.8.2431.2431 · Cited by 161
Induction of γ-Globin by Histone Deacetylase Inhibitors
McCaffrey, P. G., Newsome, D. A., Fibach, E., Yoshida, M., & Su, M. S.-S. (1997) · Blood · doi:10.1182/blood.v90.5.2075 · Cited by 118
Regulation of p21(WAF1) Expression During Normal Myeloid Differentiation
Steinman, R. A., Huang, J., Yaroslavskiy, B. B., Goff, J. P., Ball, E. D., & Nguyen, A. (1998) · Blood · doi:10.1182/blood.v91.12.4531 · Cited by 80
Freemerman, A. J., Vrana, J. A., Tombes, R. M., Jiang, H., Chellappan, S., Pb, F., & Grant, S. (1997) · Leukemia · doi:10.1038/sj.leu.2400625 · Cited by 65
Kitamura, K., Kiyoi, H., Yoshida, H., Saito, H., Ohno, R., & Naoe, T. (1997) · Leukemia · doi:10.1038/sj.leu.2400837 · Cited by 56
Self-citationMorphological reversion of sis-transformed NIH3T3 cells by trichostatin A.
Sugita, K., Koizumi, K., & Yoshida, H. (1992) · PubMed · Cited by 54
Tomonaga, M., Yoshida, Y., Tagawa, M., Jinnai, I., Kuriyama, K., Amenomori, T., Yoshioka, A., Matsuo, T., Nonaka, H., & Ichimaru, M. (1985) · Blood · doi:10.1182/blood.v66.2.350.350 · Cited by 47
Murate, T., Saga, S., Hotta, T., Asano, H., Ito, T., Kato, K., Tsushita, K., Kinoshita, T., Ichikawa, A., Yoshida, S., et al. (1993) · Experimental Cell Research · doi:10.1006/excr.1993.1219 · Cited by 43
Self-citationSano, M., & Kitajima, S. (1996) · Brain Research · doi:10.1016/s0006-8993(96)01007-4 · Cited by 14
Champelovier, P., Seigneurin, D., Leroux, D., Micouin, C., & Kolodié, L. (1989) · PubMed · Cited by 7
Morlé, F., Laverriere, A., & Godet, J. (1992) · Blood · doi:10.1182/blood.v79.11.3094.3094 · Cited by 5
Cited by
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731
Drug therapy for acute myeloid leukemia
Tallman, M. S., Gilliland, D. G., & Rowe, J. M. (2005) · Blood · doi:10.1182/blood-2005-01-0178 · Cited by 661
Sandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 502
CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS
Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095825 · Cited by 494
Metadata
- Authors
- Kosugi, H., Towatari, M., Hatano, S., Kitamura, K., Kiyoi, H., Kinoshita, T., Tanimoto, M., Murate, T., Kawashima, K., Saito, H., & Naoe, T.
- Affiliations
- Nagoya University Hospital (JP)
- Nagoya University (JP)
- Venue
- Leukemia
- Published
- 1999-09-01
- Volume
- 13
- Issue
- 9
- Pages
- 1316-1324
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2122449674
- Cited by
- 150
- References
- 41
- Citations by year
- 2026: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 1 · 2016: 4 · 2015: 1 · 2014: 3 · 2013: 5 · 2012: 3
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Shionogi
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- histone deacetylase inhibitors, acute myeloid leukemia, differentiation induction, trichostatin A, all-trans retinoic acid, vitamin D3, ATRA resistance, erythroid differentiation, p21, p16INK4a, GATA-1, beta-globin, transcriptional regulation, HL-60 cells, U937 cells
- MeSH terms
- Acute Disease, Animals, Anti-Bacterial Agents, Antineoplastic Agents, Cell Differentiation, Cell Line, Enzyme Inhibitors, Hydroxamic Acids, Leukemia, Myeloid, Megakaryocytes, Peptides, Tumor Cells, Cultured, Erythroid Precursor Cells, Gene Expression Regulation, Neoplastic, 3T3 Cells, Reverse Transcriptase Polymerase Chain Reaction, Mice, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.